All‐cause death · patients with hypertension
RAS inhibitors showed no clear difference in all‐cause death compared with thiazides (moderate certainty).
1 finding from 1 review
Cardiovascular events · patients with hypertension
RAS inhibitors showed no clear difference in total cardiovascular events compared with thiazides (moderate certainty).
1 finding from 1 review
Death or hospitalization for heart failure · patients with hypertension
RAS inhibitors probably leads to higher death or hospitalization for heart failure compared with thiazides (moderate certainty).
1 finding from 1 review
Clinically important upper GI bleeding · people admitted to intensive care units
Interventions probably leads to lower clinically important upper GI bleeding compared with placebo or no prophylaxis (moderate certainty).
1 finding from 1 review
Duration of ICU stay · people admitted to intensive care units
1 finding from 1 review
Blood transfusion · people admitted to intensive care units
H2 receptor antagonists probably leads to lower number of participants requiring blood transfusions compared with placebo or no prophylaxis (moderate certainty).
1 finding from 1 review
Serious adverse events · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important upper GI bleeding · people admitted to intensive care units
Proton pump inhibitors showed no clear difference in clinically important upper GI bleeding compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Nosocomial pneumonia · people admitted to intensive care units
Proton pump inhibitors showed no clear difference in nosocomial pneumonia compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
Proton pump inhibitors showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Duration of ICU stay · people admitted to intensive care units
1 finding from 1 review
Blood transfusion · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important upper GI bleeding · people admitted to intensive care units
Antacids may leads to lower clinically important upper GI bleeding compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Nosocomial pneumonia · people admitted to intensive care units
Interventions showed no clear difference in nosocomial pneumonia compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Nosocomial pneumonia · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
ICU mortality · people admitted to intensive care units
Antacids showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Duration of ICU stay · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood transfusion · people admitted to intensive care units
Antacids showed no clear difference in number of participants requiring blood transfusions compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Serious adverse events · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found